These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35282969)

  • 1. Re: Sarah P. Psutka, Roman Gulati, Michael A.S. Jewett, et al. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. Eur Urol. 2022;81:576-85.
    Montorsi F; Capitanio U; Rosiello G; Larcher A
    Eur Urol; 2022 Jun; 81(6):e149. PubMed ID: 35282969
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Sarah P. Psutka, Roman Gulati, Michael A.S. Jewett, et al. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. Eur Urol 2022;81:576-85.
    Wenzel M; Chun FK; Becker A
    Eur Urol; 2022 Nov; 82(5):e146-e147. PubMed ID: 35945085
    [No Abstract]   [Full Text] [Related]  

  • 3. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis.
    Psutka SP; Gulati R; Jewett MAS; Fadaak K; Finelli A; Legere L; Morgan TM; Pierorazio PM; Allaf ME; Herrin J; Lohse CM; Houston Thompson R; Boorjian SA; Atwell TD; Schmit GD; Costello BA; Shah ND; Leibovich BC
    Eur Urol; 2022 Jun; 81(6):576-585. PubMed ID: 34862099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol 2012;61:826-33.
    Procopio G; Verzoni E; De Braud F
    Eur Urol; 2012 Jul; 62(1):e5-6; author reply e7-8. PubMed ID: 22487015
    [No Abstract]   [Full Text] [Related]  

  • 5. Rebuttal from authors re: Edward M. Messing. Node positive renal cell cancer. Who can be helped? Eur Urol 2007;51:1477-8.
    Karakiewicz P; Perrotte P; Trinh QD; Patard JJ
    Eur Urol; 2007 Jun; 51(6):1478-80. PubMed ID: 17275988
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and CommunicationR. Gulati, S. P. Psutka and R. Etzioni
    Shah N; Ioffe V
    J Urol; 2020 Apr; 203(4):841-842. PubMed ID: 31845839
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: E. Jason Abel, Stephen H. Culp, Nizar M. Tannir, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10-5.
    Ozcan MF; Canda AE; Dizdar O; Altinova S; Akbulut Z; Balbay MD
    Eur Urol; 2011 Jun; 59(6):e34. PubMed ID: 21398023
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol 2021;79:783-92.
    Gao X; Chen G; Wei X
    Eur Urol; 2021 Dec; 80(6):e143-e144. PubMed ID: 34593263
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Pierre I. Karakiewicz, Nazareno Suardi, Claudio Jeldres, et al. Neoadjuvant Sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 2008;53:845-8.
    Staehler M
    Eur Urol; 2008 Oct; 54(4):950-1; author reply 951-3. PubMed ID: 18486309
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Jens Bedke, Brian I. Rini, Elizabeth R. Plimack, et al. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. Eur Urol. 2022;82:427-39.
    Zhao B
    Eur Urol; 2022 Dec; 82(6):e174-e175. PubMed ID: 36175267
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?
    Mollica V; Rizzo A; Massari F
    Eur Urol Oncol; 2020 Aug; 3(4):559-560. PubMed ID: 32553708
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Robert J. Motzer, Paul Russo, Naomi Haas, et al. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. Eur Urol 2021;79:334-8: PROTECTing Patients with Locally Advanced Kidney Cancer.
    Singla N; Pierorazio P; Allaf M; Ged Y
    Eur Urol; 2021 Jul; 80(1):e33-e34. PubMed ID: 33962807
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006: Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?
    Noel J; Huillard O; Goldwasser F
    Eur Urol; 2021 Apr; 79(4):e112. PubMed ID: 33518379
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol 2014;65:235-41.
    Bjurlin M; Elkin EB; Huang WC
    Eur Urol; 2015 Apr; 67(4):e71. PubMed ID: 25179936
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Laurence Albiges, Tom Powles, Michael Staehler, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma. Eur Urol 2019;76:151-6: Active Surveillance in Metastatic Renal Cell Cancer: Missing a Chance for Cure?
    de Joode K; van der Veldt AAM
    Eur Urol; 2020 Mar; 77(3):e76-e77. PubMed ID: 31610901
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Mesut Remzi, Michael Marberger. Renal tumor biopsies for evaluation of small renal tumors: why, in whom, and how? Eur urol 2009;55:359-67.
    Park BK
    Eur Urol; 2009 Jun; 55(6):e99-100; author reply e101-2. PubMed ID: 19286305
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034.
    Patel HD; Allaf ME
    Eur Urol; 2013 Nov; 64(5):e105-6. PubMed ID: 23910939
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Umberto Capitanio, Jens Bedke, Laurence Albiges, et al. A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel. Eur Urol. 2023;83:3-5.
    Tang Y; Hu X; Wu K; Shao Y; Li X
    Eur Urol; 2023 Mar; 83(3):e73. PubMed ID: 36526493
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Todd M. Morgan, Dominic Tang, Kelly L. Stratton, et al. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol 2011;59:923-8. Re: Umberto Capitanio, Francesco Montorsi. Does preoperative nutritional status affect survival in renal cell carcinoma? The debate continues. Eur Urol 2011;59:929-30.
    Brookman-May S; Burger M; Wieland WF; May M
    Eur Urol; 2011 Nov; 60(5):e45-6; author reply e47. PubMed ID: 21820239
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Rana R. McKay, Xun Lin, Julia J. Perkins, Daniel Y.C. Heng, Ronit Simantov, Toni K. Choueiri. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur Urol 2014;66:502-9.
    Beuselinck B; Wolter P; Broom R
    Eur Urol; 2014 Sep; 66(3):e53-4. PubMed ID: 24836152
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.